NCT02503202View on ClinicalTrials.gov

Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,197

Participants

Timeline

Start Date

August 17, 2015

Primary Completion Date

May 2, 2016

Study Completion Date

September 29, 2017

Conditions
Prevention of Ebola Infection
Interventions
BIOLOGICAL

V920 Consistency Lot A

V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection

BIOLOGICAL

V920 Consistency Lot B

V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection

BIOLOGICAL

V920 Consistency Lot C

V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection

BIOLOGICAL

V920 High-dose Lot

V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection

BIOLOGICAL

Placebo to V920

Sodium chloride 0.9%, sterile solution for intramuscular injection

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02503202 - Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) | Biotech Hunter | Biotech Hunter